🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

672 results for “Nan” Clear

  1. PHASE I STUDY TO DETERMINE THE MAXIMUM TOLERATED DOSE FOR TRICHOSTATIN A IN SUBJECTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES

    Lacuna Pharma Pty Ltd

    relapsed/refractory hematologic malignancies

    phase 1 other active

    1 trial

  2. Pegylated Recombinant Candida Utilis Uricase for Injection

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Gout

    phase 1 small molecule active

    1 trial

  3. Phase 1 First-in-Human Study of JNJ-95566692 in Participants with NHLs

    Janssen-Cilag International N.V.

    Non-Hodgkin Lymphoid Malignancies (NHLs)

    phase 1 other active

    1 trial

  4. Phase 1 Study of Oral LY3410738 in Patients with Advanced Hematologic Malignancies with IDH1 or IDH2 Mutations.

    Eli Lilly Co.

    Advanced Hematologic Malignancies

    phase 1 other active

    1 trial

  5. QL2108 injection

    Qilu Pharmaceutical (Hainan) Co.,

    Atopic Dermatitis

    phase 1 small molecule completed

    1 trial

  6. QLS1128 A-Dose 1~5 and Ritonavir

    Qilu Pharmaceutical (Hainan) Co.,

    COVID-19

    phase 1 small molecule active

    1 trial

  7. R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride + Peptides from HPV-16 E6 and E7

    PDS Biotechnology Corp

    High-risk HPV Infection and Biopsy-proven CIN1

    phase 1 mab completed

    1 trial

  8. REGN2810

    Regeneron UK Limited

    Advanced Malignancies

    phase 1 small molecule terminated

    1 trial

  9. REGN3767

    Regeneron UK Limited

    Malignancies

    phase 1 small molecule completed

    1 trial

  10. REGN421(SAR153192)

    Regeneron UK Limited

    Advanced Solid Malignancies

    phase 1 small molecule completed

    1 trial

  11. REOLYSIN®

    ONCOLYTICS BIOTECH INC

    Malignant Glioma

    phase 1 mab completed

    1 trial

  12. RJK-RT2831 dose-escalation phase Ia

    Nanjing Zenshine Pharmaceuticals

    Hematologic Malignancies

    phase 1 small molecule active

    1 trial

  13. RP-A701 is a recombinant viral vector composed of an AAV serotype rh.74 (AAVrh.74) capsid encapsulating the transgene, BCL2-associated Athanogene 3 (BAG3)

    Rocket Pharmaceuticals B.V.

    Dilated Cardiomyopathy (DCM)

    phase 1 gene therapy active

    1 trial

  14. RP-L401

    Rocket Pharmaceuticals B.V.

    Infantile Malignant Osteopetrosis

    phase 1 mab terminated

    1 trial

  15. Recombinant ADAMTS13

    Takeda

    Hereditary Thrombotic Thrombocytopenic Purpura (TTP)

    phase 1 small molecule completed

    1 trial

  16. Recombinant Humanized Anti-IL-36R Monoclonal antibody and Placebo

    Shanghai University of Traditional Chinese Medicine

    Healthy

    phase 1 small molecule completed

    1 trial

  17. Recombinant NV-A01 adenovirus injection

    The First People's Hospital of Lianyungang

    Advanced Glioblastoma Patients

    phase 1 small molecule active

    1 trial

  18. Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    COVID-19

    phase 1 mab completed

    1 trial

  19. Recombinant SARS-CoV-2 Fusion Protein Vaccine

    Livzon Pharmaceutical Group

    COVID19

    phase 1 mab completed

    1 trial

  20. Recombinant adeno-associated virus administration

    Kunming Hope of Health Hospital

    Menkes Syndrome

    phase 1 small molecule terminated

    1 trial

  21. Recombinant erythropoietin stimulating protein

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Chronic Renal Failure

    phase 1 small molecule active

    1 trial

  22. Recombinant human C1 esterase inhibitor

    Takeda

    Hereditary Angioedema (HAE)

    phase 1 small molecule completed

    1 trial

  23. Recombinant human arginase 1 Peg5000

    International Peace Maternity and Child Health Hospital

    Leukemia

    phase 1 small molecule terminated

    1 trial

  24. Recombinant human hyaluronidase PH20 (rHuPH20)

    HALOZYME THERAPEUTICS, INC.

    Healthy

    phase 1 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources